Sign in

Private company

ChemoCentryx, Inc.

American pharmaceutical preparations company based in Mountain View2

In its 2022 annual report the company says: “ChemoCentryx is an integrated United States biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. We target the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies.”56

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersMountain View, United States2
  • Incorporated inDE3
  • Business address835 Industrial Road, Suite 600, San Carlos, Ca 940703
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • LEI529900YTTXUSFQTAKY402
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 26800862

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-403.2%Operating margin4
-408.9%Net margin4
-50.3%Revenue growth, 20214
-46.0%Return on equity4
0.02×Debt to equity4
-$94.6MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development50¢$83.0M
  • Selling, general and admin48¢$78.9M
  • Interest2¢$2.7M

Out of $32.2M in revenue.4 The company lost money this year.

Financial statements

Revenue5674$32.2M in 2021+170% since 2016
0$25.0M$50.0M$75.0M$100.0M2016: $11.9M$11.9M20162017: $82.5M$82.5M2017+591%2018: $42.9M$42.9M2018−48%2019: $36.1M$36.1M2019−16%2020: $64.9M$64.9M2020+80%2021: $32.2M$32.2M2021−50%
Operating income85674-$129.9M in 2021+172% since 2015
-$150.0M-$100.0M-$50.0M0$50.0M2015: -$47.7M-$47.7M20152016: -$40.7M-$40.7M2016−15%2017: $16.5M$16.5M20172018: -$40.3M-$40.3M20182019: -$58.3M-$58.3M2019+45%2020: -$55.2M-$55.2M2020−5%2021: -$129.9M-$129.9M2021+135%
Net income85674-$131.8M in 2021+179% since 2015
-$150.0M-$100.0M-$50.0M0$50.0M2015: -$47.3M-$47.3M20152016: -$40.0M-$40.0M2016−16%2017: $17.9M$17.9M20172018: -$38.0M-$38.0M20182019: -$55.5M-$55.5M2019+46%2020: -$55.4M-$55.4M2020−0%2021: -$131.8M-$131.8M2021+138%
Fiscal year2015201620172018201920202021
Revenue$11.9M5$82.5M6$42.9M7$36.1M4$64.9M4$32.2M4
Research and development$33.2M8$37.9M5$49.5M6$62.7M7$70.3M4$77.9M4$83.0M4
Selling, general and admin$24.2M4$42.2M4$78.9M4
Operating expenses$162.1M4
Operating income-$47.7M8-$40.7M5$16.5M6-$40.3M7-$58.3M4-$55.2M4-$129.9M4
Interest$4.0K6$1.2M7$2.1M4$2.6M4$2.7M4
Income tax$08$05$06$07$04$04$04
Net income-$47.3M8-$40.0M5$17.9M6-$38.0M7-$55.5M4-$55.4M4-$131.8M4
Earnings per share-$1.088-$0.865$0.376-$0.766-$0.986
Earnings per share (diluted)-$1.088-$0.865$0.366-$0.766-$0.986

Compare ChemoCentryx, Inc. with another company

Corporate structure

ChemoCentryx, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of ChemoCentryx, Inc.

  • ChemoCentryx, Inc. Mountain View, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ChemoCentryx, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$41.0M4 Dec 31, 2021$32.0M4 Dec 31, 2020+27.9%
Accumulated depreciation$8.7M4 Dec 31, 2021$6.9M4 Dec 31, 2020+26.7%
Property and equipment, net$32.3M4 Dec 31, 2021$25.2M4 Dec 31, 2020+28.3%
Operating-lease assets (leased space)$24.8M4 Dec 31, 2021$26.9M4 Dec 31, 2020−7.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$50.0M4 Dec 31, 2021$32.3M4 Dec 31, 2020+54.7%
Marketable securities, current$214.5M4 Dec 31, 2021$404.3M4 Dec 31, 2020−46.9%
Marketable securities, non-current$97.9M4 Dec 31, 2021$23.8M4 Dec 31, 2020+311.2%
Debt securities available for sale$354.3M4 Dec 31, 2021$458.2M4 Dec 31, 2020−22.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$851.0K4 Dec 31, 2021$04 Dec 31, 2020

Leadership

Who has led ChemoCentryx, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Thomas J. Schall2012–2022

President

  1. Thomas J. Schall2012–2022

Chief financial officer

  1. Susan M. Kanaya2012–2022

Chief operating officer

  1. William Fairey2018
  2. Tausif Butt2021–2022
201520202025
Board members and other officers (22)

Timeline

  1. Oct 20, 20228-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer37
  2. Oct 18, 20228-K Shareholder vote38
  3. Sep 20, 20228-K Other events39
  4. Aug 4, 20228-K Entered a material agreement; Regulation FD disclosure40
  5. Jul 5, 20228-K Executive or director change; Regulation FD disclosure41
  6. Jun 9, 20228-K Executive or director change42
  7. Jun 1, 20228-K Executive or director change; Shareholder vote; Regulation FD disclosure43
  8. May 5, 20228-K Results of operations44
  9. May 3, 20228-K Other events45
  10. Mar 1, 20228-K Results of operations46
  11. Feb 28, 20228-K Executive or director change47
  12. Nov 12, 20218-K Regulation FD disclosure; Other events48
  13. Feb 8, 2012New chief executive Thomas J. Schall becomes CEO12

Calendar

When it reported results

  1. May 5, 2022Reported quarterly or annual results44
  2. Mar 1, 2022Reported quarterly or annual results46
  3. Nov 9, 2021Reported quarterly or annual results49

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

88 filings to the SEC since October 2021: 1 annual reports, 3 quarterly reports, 15 major events, 46 insider forms, 7 large holders, 16 other. The latest 20:

  1. Oct 31, 202215-12G EDGAR
  2. Oct 24, 20224 FORM 4 SUBMISSION EDGAR
  3. Oct 24, 20224 FORM 4 SUBMISSION EDGAR
  4. Oct 24, 20224 FORM 4 SUBMISSION EDGAR
  5. Oct 24, 20224 FORM 4 SUBMISSION EDGAR
  6. Oct 24, 20224 FORM 4 SUBMISSION EDGAR
  7. Oct 24, 20224 FORM 4 SUBMISSION EDGAR
  8. Oct 24, 20224 FORM 4 SUBMISSION EDGAR
  9. Oct 24, 20224 FORM 4 SUBMISSION EDGAR
  10. Oct 24, 20224 FORM 4 SUBMISSION EDGAR
  11. Oct 24, 20224 FORM 4 SUBMISSION EDGAR
  12. Oct 24, 20224 FORM 4 SUBMISSION EDGAR
  13. Oct 20, 202225-NSE EDGAR
  14. Oct 20, 2022S-8 POS EDGAR
  15. Oct 20, 2022S-8 POS EDGAR
  16. Oct 20, 2022POSASR EDGAR
  17. Oct 20, 20228-K EDGAR
  18. Oct 18, 20228-K EDGAR
  19. Oct 7, 2022DEFA14A EDGAR
  20. Sep 20, 2022DEFA14A EDGAR

The 88 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 0 buys and 8 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 16, 2022KANAYA SUSAN MSee RemarksSale19,898$50.95$1.0MForm 4
Aug 4, 2022Schall Thomas J.President and CEOSale130,000$50.24$6.5MForm 4
Aug 4, 2022KANAYA SUSAN MSee RemarksSale46,298$50.17$2.3MForm 4
Aug 4, 2022Tyree James LDirectorSale10,000$50.22$502.2KForm 4
Aug 4, 2022Cappel Markus J.Chief Bus. Officer & TreasurerSale7,564$50.22$379.9KForm 4
Jun 9, 2022Tyree James LDirectorSale3,863$25.66$99.1KForm 4
Dec 17, 2021Tyree James LDirectorSale37,500$35.02$1.3MForm 4
Oct 12, 2021Vifor Fresenius Medical Care Renal Pharma Ltd.10% ownerSale4,000,000$39.43$157.7MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How ChemoCentryx, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARChemoCentryx, Inc.1
  • CIK0001340652
  • Employer ID (EIN)94-32543651
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address835 Industrial Road, Suite 600, San Carlos, CA 940701
  • Phone650-210-29001
  • Shares outstanding71,355,872 as of Jul 29, 202210
  • Public float$387.1M as of Jun 30, 20214
  • On EDGAR sinceNov 9, 20071
  • Filings782 in all: 4 (431), 8-K (117), SC 13G/A (46), 10-Q (32), 3 (29), SC 13G (22), 10-K (11), DEF 14A (11)1
    All 39 form types

    DEFA14A (7), S-1/A (7), SC 13D/A (7), 424B5 (6), CORRESP (6), CT ORDER (6), UPLOAD (5), ARS (4), EFFECT (4), 5 (3), S-3 (3), 4/A (2), S-1 (2), S-8 (2), S-8 POS (2), SC 13D (2), 144 (1), 15-12G (1), 25-NSE (1), 424B1 (1), 8-A12B (1), 8-K/A (1), CERTNAS (1), DEFM14A (1), DEL AM (1), FWP (1), POSASR (1), PREM14A (1), REGDEX (1), RW (1), S-3ASR (1)

  • Latest filingsAnnual report (10-K) Mar 1, 2022
    Quarterly report (10-Q) Aug 8, 2022
    Proxy statement (DEF 14A) Apr 5, 2022
    Latest 8-K (8-K) Oct 20, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
    SEC EDGAROther events
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56